Whitehawk Therapeutics, Inc.
WHWK · XNASCIK 1422142fmd_1F9TQ3T3HAZ0A3Q4MEBNEC7AEVManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2008 to Sep 30, 2026, 68 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | – | – | 20 | 0 | 14 | 14 | 15 | 24 | 26 | 7 |
| Cost of revenue | – | – | – | – | – | 0 | 1 | 3 | 3 | 1 |
| Provision for credit losses | – | – | – | – | 0 | 0 | – | – | – | – |
| Gross profit | – | – | – | – | – | 14 | 14 | 22 | 23 | 6 |
| Research and development | 11 | 12 | 18 | 13 | 15 | 20 | 33 | 49 | 51 | 91 |
| Selling, general and administrative | – | – | – | – | – | 19 | 40 | 45 | 37 | 30 |
| Total operating expenses | 17 | 21 | 31 | 24 | 17 | 112 | – | – | – | – |
| Operating income | (17) | (21) | (11) | (24) | (3) | (111) | (63) | (72) | (67) | (114) |
| Interest expense | 0 | – | – | – | 1 | 1 | 0 | 0 | 0 | 0 |
| Interest and investment income | – | – | – | – | 0 | 0 | 2 | 6 | 4 | 6 |
| Other non-operating income (expense) | (0) | (0) | 1 | 1 | 2 | 1 | 2 | 6 | 4 | 94 |
| Income before taxes | – | – | – | – | (3) | (110) | (61) | (66) | (64) | (21) |
| Income tax expense | – | – | – | – | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income from continuing operations | – | – | – | – | (3) | (110) | (61) | (66) | (64) | (21) |
| Net income | (17) | (21) | (10) | (23) | (3) | (110) | (61) | (66) | (64) | (21) |
| Net income to common shareholders | (21) | (22) | (10) | (23) | (4) | (111) | (61) | – | – | – |